Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

HIV-associated cancer News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A recent study on lenacapavir resistance found that major resistance-associated mutations (RAMs) are rare and absent in intact HIV-1 proviral DNA. This research contributes to understanding the drug's efficacy in treating HIV infections.

A case report details gastric adenosquamous carcinoma exhibiting a pure squamous phenotype in a patient with HIV. This finding may provide insights into the tumor's behavior and its association with HIV.

A study evaluates an anti-idiotype derived germline-targeting immunogen aimed at eliciting VRC01-class precursors in human antibody transgenic mice. This research could advance understanding of antibody responses relevant to HIV.

The CDC awards approximately $750,000 to the Elizabeth Glaser Pediatric AIDS Foundation to enhance HIV care for children and reduce mother-to-child transmission. This funding is aimed at collaborating with faith-based organizations to accelerate treatment efforts.

The CDC announces a $15 million funding award to the Ministry of Health Zambia for the national HIV response for Federal Fiscal Year 2026. This funding aligns with U.S. Government goals to enhance healthcare initiatives in Zambia.

A real-world study evaluates the safety and efficacy of switching from tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide in Chinese individuals living with HIV. The findings contribute to understanding treatment options for this population.

A recent study published in PubMed explores the immunophenotype and proviral landscape of HIV-infected CD4 T cells during antiretroviral therapy. This research provides insights into the cellular mechanisms that may influence treatment outcomes in HIV patients.

The Global Burden of Disease Study 2023 highlights the ongoing impact of HIV/AIDS from 1990 to 2023, emphasizing the role of intimate partner violence in exacerbating the burden. The study also forecasts potential negative outcomes from funding cuts through 2030.

The CDC announces a $30 million award to the Ministry of Health of Ethiopia to support national HIV and tuberculosis programs. This funding is part of a cooperative agreement aimed at enhancing healthcare infrastructure in the region.

The CDC announces a $30 million cooperative agreement to fund Zambia's University Teaching Hospital for improving HIV and TB services. This funding is set for Federal Fiscal Year 2026, with continuation amounts for subsequent years.

The CDC has awarded approximately $15 million to the Public Health Center of the Ministry of Health of Ukraine to enhance HIV and tuberculosis epidemic control efforts. This funding is part of a cooperative agreement aimed at improving integrated health services in Ukraine.

A case report highlights bilateral pathological femoral fractures in a woman with HIV, attributed to long-term use of tenofovir disoproxil fumarate leading to osteomalacia. This finding underscores the need for monitoring bone health in patients on this medication.

The CDC is seeking public comment on a proposed data collection project related to the HIV Capacity Building Assistance Program. This initiative aims to enhance data management and monitoring efforts, as mandated by the Paperwork Reduction Act.

Gilead Sciences is expanding its pipeline beyond HIV, focusing on inflammation and oncology as it faces pressure to diversify. The company aims to leverage upcoming catalysts in these areas to strengthen its market position.

A long-term follow-up study investigates HIV-1 reservoir inducibility and immune phenotypes following prolonged analytical treatment interruption. The findings contribute to understanding the dynamics of HIV reservoirs and immune responses, which are critical for developing effective therapies.

GSK initiates a $2.5 billion cost-cutting plan to navigate an impending patent cliff affecting its HIV drug franchise. The specifics of potential job cuts remain undisclosed as the company prepares for financial adjustments.

Summit is addressing investor skepticism regarding ivonescimab with a new analysis, while Gilead and Merck introduced data for a once-weekly HIV tablet. Additionally, a new competitor in the psychedelics space has emerged.

ViiV Healthcare will present new data on an INSTI-powered HIV treatment at AIDS 2026, highlighting advancements in both treatment and pre-exposure prophylaxis (PrEP). This presentation aims to showcase innovative approaches in HIV management.

A recent study highlights reversible HIV-associated nephropathy and encephalomyelopathy as initial presentations of advanced untreated HIV. This research underscores the need for early detection and treatment of HIV to prevent severe complications.

Not rare diseases news,news about your rare disease.